These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38261231)

  • 1. Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults.
    Boinpally R; Trugman J
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):688-695. PubMed ID: 38261231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
    Goadsby PJ; Tepper SJ; Watkins PB; Ayele G; Miceli R; Butler M; Severt L; Finnegan M; Szegedi A; Trugman JM; Jakate A
    Cephalalgia; 2019 Dec; 39(14):1753-1761. PubMed ID: 31537107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
    Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
    Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.
    Ankrom W; Bondiskey P; Li CC; Palcza J; Liu W; Dockendorf MF; Matthews C; Panebianco D; Reynders T; Wagner JA; Jakate A; Mesens S; Kraft WK; Marcantonio EE
    Clin Transl Sci; 2020 May; 13(3):462-472. PubMed ID: 31899602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
    Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
    CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubrogepant for the Treatment of Migraine.
    Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
    N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
    Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
    JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubrogepant for the treatment of migraine.
    Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
    Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling.
    Li CC; Dockendorf M; Kowalski K; Yang B; Xu Y; Xie I; Kleijn HJ; Bosch R; Jones C; Thornton B; Marcantonio EE; Voss T; Bateman KP; Kothare PA
    J Clin Pharmacol; 2018 Mar; 58(3):294-303. PubMed ID: 29136283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
    Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
    Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Clin Pharmacol Ther; 2020 Apr; 107(4):1014-1022. PubMed ID: 31628854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
    Dodick DW; Goadsby PJ; Schwedt TJ; Lipton RB; Liu C; Lu K; Yu SY; Severt L; Finnegan M; Trugman JM
    Lancet; 2023 Dec; 402(10419):2307-2316. PubMed ID: 37979595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy, tolerability, and safety of ubrogepant.
    Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ
    Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
    Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
    Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
    Hutchinson S; Silberstein SD; Blumenfeld AM; Lipton RB; Lu K; Yu SY; Severt L
    Cephalalgia; 2021 Aug; 41(9):979-990. PubMed ID: 33874756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium.
    Boinpally R; Lu K
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):270-277. PubMed ID: 34811955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.